In encouraging news regarding melanoma therapy, researchers found that a personalized vaccine continues to keep cancer cells in check four years after patients received it.
Archive | Clinical Trials
Melanoma Vaccine from NeoVox Shows Anti-Tumor Response Four Years Later
Posted in Melanoma News, Health Professionals, Clinical Trials, Publications, Scientific Publications
Eganelisib/Nivolumab Combo Shows Positive Responses in Head and Neck Carcinoma, Melanoma
Positive response and disease control rates were observed in 2 separate studies when patients with head and neck squamous cell carcinoma (HNSCC) and melanoma received the combination of eganelisib (IPI-549), a selective PI3K-? inhibitor, and nivolumab (Opdivo).
Posted in Melanoma News, Health Professionals, Clinical Trials, Publications, Scientific Publications
Avastin Plus Chemotherapy Improves Progression-Free and Overall Survival in Mucosal Melanoma
Avastin (bevacizumab) with carboplatin plus paclitaxel improved overall survival (OS) and progression-free survival (PFS) compared with carboplatin and paclitaxel alone in patients with metastatic mucosal melanoma, according to findings from a phase 2 study published in the Journal of Clinical Oncology.
Posted in Melanoma News, Health Professionals, Clinical Trials, Publications, Scientific Publications
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 /PRNewswire/ — IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced First-Patient-In (FPI) in the Phase 1 combination study of IDE196 and crizotinib, a cMET inhibitor, in metastatic uveal melanoma (MUM).
Posted in Melanoma News, Health Professionals, Clinical Trials
